Pneumococcal vaccine supply strained as elderly turned away from pharmacies

An 89-year-old woman in Adelaide's western suburbs never got her pneumococcal vaccine. Her daughter called ahead to the Henley Beach pharmacy, hoping to book an appointment, only to be told the vaccine wasn't in stock. She tried other pharmacies. Same answer each time. The free vaccine for the elderly—the one the government had just made available to her mother's age group—simply wasn't there.

This is not, according to health authorities, a shortage. It is, they insist, a matter of uneven distribution. But the distinction feels thin to people turned away from pharmacies across South Australia in recent weeks.

The pneumococcal vaccine protects against pneumonia, meningitis, and bloodstream infections—diseases that carry real weight for older people and other vulnerable groups. In July, the Commonwealth government expanded who could access it for free: anyone over 65, Aboriginal and Torres Strait Islander people over 25, and at-risk adults over 18. The same month, a new vaccine called Capvaxive became available, one that covers 21 strains of pneumococcal disease, a significant improvement over previous options. Demand surged almost immediately.

SA Health's chief public health officer, Nicola Spurrier, acknowledged the situation plainly: roughly 70 percent of available vaccines have already been administered since the program began. She framed the problem as a Commonwealth responsibility. "Vaccine supply is the responsibility of the Commonwealth Government, and we are in ongoing discussions with them to release additional supply," she said. The advice to those seeking the vaccine was to ring around—contact your GP, try different pharmacies, check with other providers in your area.

When a reporter made calls on a single morning, the picture was scattered. Chemist Warehouse locations in Port Adelaide and Norwood had no stock. National Pharmacies in Salisbury was empty. But TerryWhite Chemmart in Walkerville had it, as did National Pharmacies in Brighton. The vaccine existed somewhere, just not everywhere.

Dr. Peter Subramaniam, president of the Australian Medical Association's South Australian branch, framed the problem differently. GPs across the country had been raising concerns about supply delays. He pointed to the collision of two forces: a genuinely new vaccine that had only recently been approved, which always strains supply chains, and a sudden expansion in who could receive it. "What we now have is a combination of a new vaccine, and of course that will impact on supply, as well as increased demand," he said. He was calling urgently on both the Commonwealth and SA Health to publish a timeline for when supply would stabilize.

The stakes are not abstract. In South Australian hospitals, pneumonia in elderly patients takes up significant bed space and contributes to the ramping—the bottleneck of patients waiting in emergency departments. Pneumococcal disease is not seasonal; it circulates year-round. Every person who gets vaccinated is one fewer person likely to need hospitalization. Subramaniam urged people in at-risk groups to register with their GPs or Aboriginal health services to get on priority lists. He also offered a practical note: don't skip your flu, COVID, or RSV vaccines while waiting for the pneumococcal one. Protection is layered.

A spokesperson from the Department of Health, Disability and Ageing acknowledged "localised distribution issues"—some sites oversupplied, others undersupplied. The department said it had worked with manufacturers to accelerate deliveries and was coordinating with states and territories to restore normal availability. The word "normalise" appeared in multiple official statements, a small acknowledgment that things are not normal now.